Safello’s net sales came in 9% below Redeye Research Estimates (RRe) at SEK194m, growing 1% y/y.
The FDA submission is progressing toward the finish line, as illustrated by the more precise expecte...
Redeye provides an initial take following Paxman’s Q1 2025 report.
1% organic growth (cons 4%) and EBITA -13% vs cons Reiterates 2025 guidance of EBITA 2024, Q1 EBITA ...
Redeye updates on EG7 after Q1-results where sales came in above expectations while EBITDA was somew...
Redeye provides an update on Thunderful Group following its Q1 2025 report, which was better than ex...
Redeye updates its estimates and valuation following Navigo releasing its Q1 2025 report.
We make limited revisions to our 2026-27 estimates, lowering adjusted EBIT by ~1%.
Titania (”Titania” eller ”Bolaget”) publicerade den 15 maj år 2025 Bolagets delårsrapport för det fö...
Umida Group (”Umida”, ”koncernen” eller ”bolaget”) publicerade den 15 maj 2025 bolagets delårsrappor...
First Venture (”First Venture” eller ”Bolaget”) publicerade den 15 maj 2025 Bolagets delårsrapport f...
Obducat AB (publ) (”Obducat” eller ”Bolaget”) är en ledande leverantör av litografilösningar och har...
Redeye provides a research update following the Q1 report published by OncoZenge earlier today.
Nosa Plugs AB (“Nosa Plugs” or the “Company”) published the Company’s interim report for the first q...
Redeye provides its first take on Oncopeptides' Q1 report 2025, published this morning.
Miss driven by Pulp Paper market better, but still not good enough Outlook remains muted Miss drive...
Q1 EBIT SEK 164m (vs. ABGSCe 253m) Pome 75% completed, 25% remaining Sales of Dållebo, Boarp and Fåg...
Redeye provides its first take on Camurus’ Q1 report 2025, published this morning.
Redeye comments on Xspray following yesterday evening’s announcement of a PDUFA date set for early O...
Redeye comments on EG7 Q1-results which saw strong topline while EBITDA was somewhat softer than exp...
